Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations

Michael M. Witte, Norman L. Foster, Adam S. Fleisher, Monique M. Williams, Kimberly Quaid, Michael Wasserman, Gail Hunt, J. Scott Roberts, Gil D. Rabinovici, James L. Levenson, Ann Marie Hake, Craig A. Hunter, Luann E. Van Campen, Michael J. Pontecorvo, Helen M. Hochstetler, Linda B. Tabas, Paula T. Trzepacz

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark can be detected antemortem. Practitioners and patients need to better understand potential diagnostic benefits and limitations of amyloid-PET and the complex practical, ethical, and social implications surrounding this new technology. To complement the practical considerations, Eli Lilly and Company sponsored a Bioethics Advisory Board to discuss ethical issues that might arise from clinical use of amyloid-PET neuroimaging with patients being evaluated for causes of cognitive decline. To best address the multifaceted issues associated with amyloid-PET neuroimaging, we recommend this technology be used only by experienced imaging and treating physicians in appropriately selected patients and only in the context of a comprehensive clinical evaluation with adequate explanations before and after the scan.

Original languageEnglish (US)
Pages (from-to)358-367
Number of pages10
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume1
Issue number3
DOIs
StatePublished - Sep 1 2015

Keywords

  • Alzheimer's disease
  • Amyloid-β
  • Bioethics in neurology
  • Biomarkers
  • Dementia
  • Diagnostic use
  • Mild cognitive impairment
  • Positron emission tomography

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations'. Together they form a unique fingerprint.

  • Cite this

    Witte, M. M., Foster, N. L., Fleisher, A. S., Williams, M. M., Quaid, K., Wasserman, M., Hunt, G., Roberts, J. S., Rabinovici, G. D., Levenson, J. L., Hake, A. M., Hunter, C. A., Van Campen, L. E., Pontecorvo, M. J., Hochstetler, H. M., Tabas, L. B., & Trzepacz, P. T. (2015). Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 1(3), 358-367. https://doi.org/10.1016/j.dadm.2015.06.006